Oncview


EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer

November 18th 2021

A leading expert in lung cancer provides insights on recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.

Recent Updates in Treatment of Non-Metastatic Castration Resistant Prostate Cancer

November 16th 2021

Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.

Immunotherapy Response Monitoring in Lung Cancer

October 18th 2021

Roy S. Herbst, MD, PhD, reviews currently available treatment options in immunotherapy in non-small-cell lung cancer and approaches to monitoring treatment response.

PARP Inhibitors in Prostate Cancer

October 15th 2021

Oliver Sartor, MD, gives an overview of the use of PARP inhibitors to treat metastatic castration-resistant prostate cancer.

Immunotherapy Response Monitoring in Melanoma

October 12th 2021

John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.

Updates in Therapies of Relapse/Refractory Follicular Lymphoma

September 7th 2021

Connie Batlevi, MD, PhD, explains the treatment options for relapsed/refractory follicular lymphoma and discusses a recent drug approval.

Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

July 6th 2021

Javier L. Munoz, MD, MS, FACP, explains the treatment options for relapsed/refractory follicular lymphoma and provides insight into a recent clinical trial.

NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy

June 28th 2021

Recommendations for utilizing genomic testing to aid in treatment decisions for early-stage HR+ breast cancer based on updates to the NCCN guidelines.

Management of Relapsed/Refractory Follicular Lymphoma

May 12th 2021

Sameh Gaballa, MD, reviews the treatment options for relapsed/refractory follicular lymphoma and future treatment options.

Updates in the Management of Extensive-Stage Small Cell Lung Cancer

May 10th 2021

Considerations for adding immunotherapy to the armamentarium for frontline treatment of extensive-stage small cell lung cancer.